Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 5,102 Shares

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell sold 5,102 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $1.97, for a total value of $10,050.94. Following the completion of the transaction, the chief executive officer owned 657,737 shares in the company, valued at approximately $1,295,741.89. This trade represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Joseph Oconnell also recently made the following trade(s):

• On Wednesday, January 7th, Daniel Joseph Oconnell sold 37,755 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.99, for a total value of $75,132.45.
• On Monday, January 5th, Daniel Joseph Oconnell sold 4,649 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total value of $9,158.53.

Acumen Pharmaceuticals Stock Performance

Shares of NASDAQ ABOS traded up $0.03 during midday trading on Wednesday, hitting $1.99. 220,171 shares of the company’s stock traded hands, compared to its average volume of 159,170. The firm has a fifty day moving average of $1.96 and a 200 day moving average of $1.67. Acumen Pharmaceuticals, Inc. has a 1 year low of $0.86 and a 1 year high of $2.46. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The stock has a market capitalization of $120.53 million, a price-to-earnings ratio of -0.90 and a beta of 0.23.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.19. On average, analysts forecast that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Wall Street Analyst Weigh In

ABOS has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Tuesday, October 14th. Wall Street Zen raised Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Bank of America lowered their price objective on Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.75.

Institutional Trading of Acumen Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. bought a new stake in Acumen Pharmaceuticals in the third quarter worth $27,000. Marex Group plc purchased a new stake in shares of Acumen Pharmaceuticals in the second quarter valued at $39,000. AQR Capital Management LLC purchased a new stake in shares of Acumen Pharmaceuticals in the first quarter valued at $46,000. Qube Research & Technologies Ltd lifted its holdings in shares of Acumen Pharmaceuticals by 160.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company’s stock worth $67,000 after acquiring an additional 35,424 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Acumen Pharmaceuticals by 544.1% during the 1st quarter. Invesco Ltd. now owns 127,798 shares of the company’s stock worth $141,000 after purchasing an additional 107,956 shares during the period. Hedge funds and other institutional investors own 71.01% of the company’s stock.

More Acumen Pharmaceuticals News

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Neutral Sentiment: No stated reason in filings — The disclosures show routine Form 4 sales but do not explain whether trades were pre‑planned or for personal liquidity/diversification; that ambiguity leaves market interpretation open.
• Negative Sentiment: CEO Daniel Joseph O’Connell sold a total of 47,506 shares across Jan. 5–7 (individual trades of 4,649; 5,102; and 37,755 shares), receiving about $94.3k in proceeds; the largest single trade (37,755 shares) was reported as a 5.74% reduction in his stake. Read More.
• Negative Sentiment: CFO Matt Zuga sold 14,905 shares over Jan. 5–7 (4,000; 5,100; 5,805), totaling roughly $29.4k in proceeds and small single‑trade ownership reductions (1.73%–2.61%). Read More.
• Negative Sentiment: COO Russell Barton sold 9,318 shares over Jan. 5–7 (4,000; 3,618; 1,700), raising about $18.4k and reducing his stake by small single‑trade percentages (1.32%–2.94%). Read More.
• Negative Sentiment: Insider Eric Siemers sold 10,834 shares on Jan. 5–6 (4,000; 6,834), for about $21.3k in proceeds and reported ownership reductions of ~2.35%–4.11% per trade. Read More.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.